Share on StockTwits

Oncomed Pharmaceuticals (NASDAQ:OMED) Director Deepika Pakianathan purchased 80,203 shares of the stock on the open market in a transaction dated Thursday, August 21st. The stock was purchased at an average price of $18.98 per share, with a total value of $1,522,252.94. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

OMED has been the subject of a number of recent research reports. Analysts at Zacks downgraded shares of Oncomed Pharmaceuticals from a “neutral” rating to an “underperform” rating in a research note on Tuesday, August 12th. They now have a $15.00 price target on the stock. Analysts at Mizuho reiterated a “buy” rating on shares of Oncomed Pharmaceuticals in a research note on Friday, June 13th.

Oncomed Pharmaceuticals (NASDAQ:OMED) traded up 2.84% on Friday, hitting $19.55. 74,671 shares of the company’s stock traded hands. Oncomed Pharmaceuticals has a 1-year low of $12.07 and a 1-year high of $42.34. The stock has a 50-day moving average of $20.89 and a 200-day moving average of $26.36. The company’s market cap is $581.8 million.

Oncomed Pharmaceuticals (NASDAQ:OMED) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.50. The company had revenue of $6.00 million for the quarter, compared to the consensus estimate of $21.28 million. Analysts expect that Oncomed Pharmaceuticals will post $-1.35 EPS for the current fiscal year.

OncoMed Pharmaceuticals, Inc (NASDAQ:OMED) is a clinical development-stage biopharmaceutical company.

Receive News & Ratings for Oncomed Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.